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Abstract
The placenta is a critical organ during pregnancy, essential for the provision of an optimal in-
trauterine environment, with fetal survival, growth, and development relying on correct placental
function. It must allow nutritional compounds and relevant hormones to pass into the fetal blood-
stream and metabolic waste products to be cleared. It also acts as a semipermeable barrier to
potentially harmful chemicals, both endogenous and exogenous. Transporter proteins allow for
bidirectional transport and are found in the syncytiotrophoblast of the placenta and endothelium
of fetal capillaries. The major transporter families in the human placenta are ATP-binding cassette
(ABC) and solute carrier (SLC), and insufficiency of these transporters may lead to deleterious
effects on the fetus. Transporter expression levels are gestation-dependent and this is of consid-
erable clinical interest as levels of drug resistance may be altered from one trimester to the next.
This highlights the importance of these transporters in mediating correct and timely transplacental
passage of essential compounds but also for efflux of potentially toxic drugs and xenobiotics. We
review the current literature on placental molecular transporters with respect to their localization
and ontogeny, the influence of fetal sex, and the relevance of animal models. We conclude that a
paucity of information exists, and further studies are required to unlock the enigma of this dynamic
organ.
Summary Sentence
This review summarises the existing knowledge of human placental molecular transporters (SLC
andABC superfamilies).Wehighlight areaswhere greater andmore accurate knowledge is required
and discuss weaknesses of animal models for the human.
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Introduction
The placenta is an important, ephemeral organ, and optimal function
is essential for normal fetal development and a successful pregnancy.
It is well known that the placenta acts as a conduit to supply nutrients
and removemetabolic waste from the fetus. The placenta also synthe-
sizes and secretes hormones such as estrogens, progestogens, human
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Figure 1. Transporting epitheliumof the placenta andmolecular transporter function. Amoleculemust be transported (or diffuse) through the syncytiotrophoblast
and endothelium of the fetal capillary to access the fetal compartment. (A) Molecular transporter proteins are positioned in the maternal-facing apical and fetal-
facing basolateral membranes and in the endothelium of fetal capillaries. (B) Possible pathways across the syncytiotrophoblast. A molecule can use transporter
proteins, passive diffusion, or pinocytosis to cross the syncytiotrophoblast membranes. The molecule can be transported intact or may be metabolized first.
The syncytiotrophoblast also retains certain molecules for its own use. (C) Superfamilies of genes coding for molecular transporters found in the placenta.
SLC can be divided into gene subfamilies SLCO and SLC22A. ABC consist of seven gene subfamilies: ABCA, ABCB, ABCC, ABCD, ABCE, ABCF, ABCG although
ABCE and ABCF are unlikely to have transporter function. A list of corresponding proteins can be found in Table 1. (D) Mechanism of transport for SLC proteins.
Compounds can enter/exit the cell coupled to anothermolecule, passively down its concentration gradient or in exchange for anothermolecule. SLC transporters
can be bidirectional although they mainly allow for placental uptake of molecules. (E) Mechanism of transport for ABC proteins. ABC transporters actively efflux
compounds against their concentration gradient. ATP hydrolysis is required for a conformational change of the transporter protein to allow uptake and expulsion
of the substrate from the cell.
chorionic gonadotrophin, and human placental lactogen which are
essential for the establishment and maintenance of the pregnancy.
Vitally, it acts as a gate keeper, regulating the flux of drugs and
xenobiotic compounds in and out of the fetal compartment. It is the
mother that ensures such compounds are present in the fetoplacen-
tal environment and their availability greatly depends on maternal
lifestyle factors including but not limited to environmental chemi-
cals (e.g., endocrine disruptors and environmental toxins), pharma-
ceuticals, illicit/recreational drugs, tobacco smoke constituents, and
alcohol. It is important to note that such exposures may harm the
fetus not only directly but also indirectly by perturbing placental
function itself, impacting on fetal health without ever reaching the
fetal compartment.
It is increasingly recognized that after parturition the placenta
is not simply a waste by-product of pregnancy, but rather an or-
gan that carries a fingerprint about important pregnancy parameters
(e.g., pregnancy progression, substance exposure, fetal metabolism).
This “placental fingerprint”, unique to every pregnancy, potentially
encompasses biomarkers that can be used to make predictions about
the offspring’s health. For example, the shape and size of the term
placenta can predict blood pressure in childhood, with reduced pla-
centation (smaller placentas) resulting in higher systolic blood pres-
sure due to undernutrition [1]. Pregnancy disorders such as intrauter-
ine growth restriction, pre-eclampsia, and even miscarriage remain
relatively poorly understood but their etiology is likely to include
elements of placental dysfunction [2, 3]. In addition to perinatal ad-
versities, the “Barker Hypothesis” (also known as “fetal origins of
adult disease hypothesis”) postulates that long-term health problems
can manifest due to perturbed fetal programming [4]. Since placental
function is a determinant of both fetal development and postnatal
health, a better understanding of placental molecular processes that
define the placental fingerprint (i.e., which genetic/molecular/gross
morphology markers the placenta has at term) will improve our
understanding of these complications and will aid the detection of
susceptible individuals.
The placenta is a highly dynamic structure throughout its 9-
month lifespan, which not only grows in proportion to the fetus
but also changes both structurally and morphologically. The de-
mand for increased feto-maternal communication during gestation
dictates branching and development of placental mesenchymal villi
into terminal villi [5] thereby increasing the transport epithelial in-
terface. In the later stages of the first trimester, the placenta is fully
functional and serves the ever-increasing requirements of the fetus.
Global gene expression is adjusted constantly and genes relating to
metabolism are highly expressed in the first trimester whereas sig-
nal transduction pathways are more prominent in term placenta [6].
Due to a dynamic molecular environment, the profile of transcripts
encoding molecular transporters adapts throughout the pregnancy
as discussed below.
Transplacental transport
The placenta is the first fetal organ to be fully developed during
pregnancy. At around 7–12 days postconception, the epithelium of
the placenta, the syncytiotrophoblast, invades the endometrium [7].
The syncytiotrophoblast is the transporting epithelium of the human
placenta and its formation initiates an active border between mother
and fetus, enabling molecular exchanges between the two. It is com-
posed of an apical brush border which is bathed in a maternal blood
lacunae and a basolateral membrane which encircles branches of the
fetal capillary tree (Figure 1A). For a molecule to translocate from
mother to fetus and vice versa, it must cross the syncytiotrophoblast,
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Table 1. ABC and SLC transporters known to show expression in the human placenta.
Syncytiotrophoblast
Transporter localization Substrates/function References
ABCA1 Apical Cholesterol, phospholipids [99–101]
ABCB1 Apical Drug resistance (antibiotics, antiemetic, cardiac drugs, HIV protease inhibitors) [15, 16, 28]
ABCB4 Basolateral Bile acids [24, 38]
ABCC1 Apical Folate [28, 32]
ABCC2 Apical Folate, bilirubin, role in chemoprotection and detoxification [32, 34, 102, 103]
ABCC3 Apical Bilirubin [102]
ABCC4 Apical Conjugated bile acids [102]
ABCC5 Basolateral Cyclic nucleotides [35]
ABCC7 Apical Chloride transport [104]
ABCG1 Basolateral Cholesterol, phospholipids [100]
ABCG2 Apical Drug resistance [14, 105]
SLCO2A1 Unknown Prostaglandin [48]
SLCO2B1 Basolateral Sulfated steroids (DHEAS), glutamate [49, 50]
SLCO4A1 Apical Thyroid hormones [51]
SLCO1A2 Apical Thyroid hormones, bile acids, conjugated steroid hormones [46, 47]
SLCO1B1 Apical Bile acids [24]
SLCO3A1 Apical Bile acids [24]
SLC22A6 Unknown Drug xenobiotic eliminator [56]
SLC22A11 Basolateral Sulfated steroids (DHEAS) [57, 58]
SLC22A3 Basolateral Cationic compounds [52]
SLC22A5 Apical Lactate, folate, carnitine [53–55]
SLC22A4 Apical Lactate, folate [59]
where it may be metabolized (Figure 1B), and the endothelium of
the fetal capillary. Transplacental transport involves passive diffu-
sion, pinocytosis, and facilitated and active transport via molecular
transporter proteins which also support the barrier function of the
placenta. Suboptimal placental performance may, therefore, result
by disruption of the mechanisms that control those three modes of
molecular transportation. Active transport via molecular transport
proteins controls the flux of a wide variety of compounds and can be
tightly regulated by controlling expression, localization, and activity
of these transport proteins. For instance, polarized localization of
transporter proteins in the syncytiotrophoblast and the endothelium
of the fetal capillary can control directionality of the molecular flux
between the mother and the fetus.
Solute carriers (SLC) and ATP-binding cassette proteins (ABC)
are twomajor superfamilies of mammalian transporters. A schematic
diagram of the SLC and ABC gene families is shown in Figure 1C.
SLC transporters are capable of bidirectional transport but mainly
deal with influx of substrates (Figure 1D) and can be further clas-
sified into subfamilies SLCO and SLC22A. ABC transporters are
involved in substrate efflux (Figure 1E) and include subcategories
A–F although it is considered unlikely that E and F have transporter
function as they do not encode transmembrane domains [8]. Both
superfamilies are involved in drug transport with ABC proteins more
likely to govern fetal protection due to their active efflux properties,
which move harmful xenobiotics/drugs away from the fetal circula-
tion. Although many SLC and ABC transporters have been found
in the placenta, very few have been characterized in terms of quan-
tity, localization, gestational expression, degree of functionality, and
substrate preference within the placenta. Membrane localization of
some transporters has been well defined in the human although there
is disagreement in the literature about how expression changes dur-
ing gestation (Table 1).
Over- or underexpression of transporters would be expected to
have effects on delivery and clearance of molecules at the maternal–
fetal barrier impacting on fetal growth and health. For example,
increased molecular transport, as seen in some diabetic mothers
[9], could lead to an abnormally large fetus increasing the risk of
metabolic syndromes later in life [10]. Conversely, malfunction or
underexpression of transporters, or even competition for binding
sites between nutrients and xenobiotics [11], could cause subopti-
mal delivery of nutrients to the fetus and may lead to growth re-
striction and concomitant health-associated risks for the neonate
including cardiovascular risk [12] and type 2 diabetes [13]. These
examples highlight the importance of appropriate and timely pla-
cental regulation of transporter expression. Recognizing transporter
expression dynamics across fetal parameters such as gestation, sex,
and maternal lifestyle has the potential to allow us to assess lev-
els of protection offered by the placenta, and to identify instances
of increased susceptibility, especially during critical periods such as
organogenesis.
This review will discuss molecular transport proteins of the SLC
and ABC gene superfamilies in the placenta, their localization and
their expression profile across the trimesters. The review concen-
trates on data derived from studies using human tissue or human-
derived cell lines due to the vast interspecies differences in placental
structure and function, as discussed below.
ABC superfamily
ABC proteins actively transport physiologically relevant compounds
such as inorganic ions, glucose, amino acids, metal ions, choles-
terol, and phospholipids. In addition to this, they have a protective
function by acting as efflux pumps to move pharmaceuticals and
xenotoxicants away from the fetus and into the maternal circulation
and they are the most widely studied transporter family within the
placenta. Over 50 ABC transporters have been identified in humans
and three subfamilies are involved in drug/xenobiotic efflux: ABCB,
ABCC, and ABCG proteins. Many of those transporters have been
found in the human placenta at the transcript and/or protein level
(Figure 2).
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Figure 2. Molecular transporter transcripts with confirmed syncytiotrophoblast location in the human placenta and their direction of transport. SLC (orange)
and ABC (blue) are found in both apical (maternal-facing) and basolateral (fetal-facing) membranes. As seen by the schematic, understanding of complete
transplacental routes for compound movement is incomplete. Grey dashed line indicates the transporter has been found to be expressed on both membranes.
It is likely that many molecules must use a combination of transporters to cross the membrane and as many transporters have common substrates, this is
entirely possible. Substrates mentioned here are generalized substrates of the superfamilies.
ABCB transporters
The ABCB subfamily is the most extensively studied of the ABC
transporters due to its involvement in drug resistance.ABCB1 and its
corresponding protein product (also known as P-glycoprotein (P-gp))
are of particular interest in the placenta as they are highly abundant
[14]. So much so that ABCB1 is also known as the “ABC placental
transporter” and was the first discovered to offer fetal protection
against toxicity. The apical membrane of the syncytiotrophoblast is
enriched with ABCB1 [15], which supports its function as a drug
extrusion pump from the placenta back toward the maternal circu-
lation. This avoids drug build-up in the placenta and escape toward
the fetus. Known substrates of ABCB1 include cytotoxic, antiemetic
and cardiac drugs, antibiotics, and HIV protease inhibitors [16]. It
has been reported that ABCB1 is significantly upregulated (30%) in
placentas that are exposed tomethadone (with or without heroin and
cocaine), a known substrate of this transporter [17]. Many studies
have reported that mRNA and protein levels decrease significantly
from the first to third trimesters in the human placenta [18–21].
A possible explanation for this marked reduction in human pla-
cental ABCB1 could be the early need for retrograde transport of
drugs/chemicals during sensitive critical periods of organogenesis.
ABCB4 is involved in bile acid transport and is believed to show
drug interaction profiles similar to those of ABCB1 [22]. Its basal
location in syncytiotrophoblast cells [23] suggests that it moves
molecules out of the placenta, thereby potentially protecting the pla-
centa from chemotherapeutic drugs. ABCB4 transcript expression
has been reported to be fourfold higher in the third trimester com-
pared to first [24] although why expression increases towards term is
unclear. The importance of this transporter is seen in cases where the
mother carries an ABCB4 mutation, causing intrahepatic cholestasis
of pregnancy and impaired transplacental bile acid transport which
can sometimes result in fetal death [25].
ABCC transporters
The ABCC gene subfamily currently consists of seven multidrug re-
sistance proteins [26] which transport conjugated and unconjugated
organic ions and act as drug efflux pumps. Four of these proteins
have been well characterized in the human placenta and ABCC1
is more abundant in placenta than in liver or kidney [27]. ABCC
transporters are localized on opposing sides of the syncytium which
may give us insight to their physiological roles. ABCC2 and ABCC3
can be found on the apical membrane, directing solutes toward the
mother whilst ABCC1 and ABCC5 are localized basolaterally and
would be expected to move molecules toward the fetus. This means
that the latter two transporters would not be expected to play a role
in reducing fetal exposure unless there was a change in expression
levels. There is also evidence of ABCC1 localization on the apical
membrane and high expression levels in the fetal capillary endothe-
lium of both ABCC1 and ABCC3 [28]. These transporters also help
in the clearance of biliary substances from fetal liver to maternal
circulation, which is essential to avoid harmful build-up [29].
Another important substrate of the ABCC group is folate which
is so essential to avoid neural tube defects in the fetus that women
are advised to take extra supplementation during the periconceptual
period [30]. ABCC1 and ABCC2 assist in folate transport across
the maternal–fetal barrier. Currently, studies of ABCC1 expression
levels during development are contradictory with levels reported to
either increase [31] or decrease [32] with gestational age. If the age-
related increase is correct, it could indicate increasing demand during
a period of accelerated fetal growth and aligns with clinical guide-
lines for folic acid supplementation during the early stages of preg-
nancy. Conversely, if the reported decrease in ABCC1 is correct, this
could suggest that this transporter is important in the earlier stages
of pregnancy, during establishment of the placenta, and that folate
is preferentially moved via other transporters later on. It should be
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noted that, either way, the fetus has chronic requirements for folic
acid as there is evidence that it is required in other processes essential
for a progressing pregnancy (e.g., angiogenesis) [33]. Nevertheless,
the contradiction between the studies of [31] and [32] needs to be re-
solved in order to understand the role of ABCC1 in human placental
function. ABCC2 is involved in the excretion of conjugated bilirubin
and drugs, including anticancer pharmaceuticals [26]. ABCC2 has
been shown by two groups to increase in the placenta during preg-
nancy with an associated increase in bilirubin expulsion, [32, 34].
ABCC5 transports cyclic nucleotides and is in a fetal-facing position
on the syncytiotrophoblast; thus, it is unlikely to have a role in fe-
tal protection. ABCC5 and its transcript, ABCC5, decrease across
gestation [35].
ABCG transporters
Transporters in this family with identified functions in the pla-
centa include ABCG1, involved in cholesterol transport, and ABCG2
(more commonly known as breast cancer resistance protein (BCRP))
involved with drug resistance. The placenta expresses higher levels
of ABCG2 than any other organ [36]. ABCG2 has many exogenous
and endogenous substrates and shares some of these with ABCB1.
ABCG2 is localized to the apical membrane of syncytiotrophoblasts
and the endothelium of fetal capillaries [37]. It has been hypothe-
sized that ABCG2 is the placental “survival factor” during placental
maturation and offers protection from cytokine-induced apoptosis
[38]. ABCG2 may also be susceptible to maternal bisphenol A and
para-nonylphenol exposure both of which are associated with down-
regulation of the protein [39].
Expression patterns of ABCG2 during pregnancy remain uncer-
tain due to discrepancies in the literature [18, 21, 39–42]. More
studies are needed to single out the functionally important reasons
for these differences which may simply reflect cohort variation or
may be due to differences in methodology. Variations in the normal-
izing genes used may also add to discrepancies in the literature as
there are global, sex-dependent gene changes in the placenta across
pregnancy and use of a stable combination of housekeeping genes is
essential for the production of meaningful data [43]. Studies which
correctly account for fetal sex, cover as many gestational weeks as
possible and establish the most stable method of normalization are
needed.
SLC superfamily
This superfamily is extremely large with 55 families and 300 mem-
bers (SLC1-20 SLC22-47 then SLCO2-6 and uncoupling protein
UCP1-3) [44] which can be categorized according to Figure 1C.
Their positions within the syncytiotrophoblast can be seen in Fig-
ure 2. SLCs have been identified in almost every human epithelium
and were exhaustively reviewed by Roth et al. in 2012 [45]. Not
all of these are found, or are functional, in the human placenta,
and this section will only discuss transporters relevant to the in
utero environment. Previous studies have reported placental expres-
sion of SLCOs (SLCO1A2 [46, 47], SLCO1B1 [24], SLCO3A1 [24],
SLCO2A1 [48], SLCO2B1 [49, 50], SLCO4A1 [51], and low expres-
sion of SLCO6A1) and SLC22As (SLC22A3 [52], SLC22A5 [53–55],
SLC22A6 [56], SLC22A11 [57, 58] with SLC22A1, SLC22A2,
SLC22A4 [59] showing weak expression) (see Table 1). The pla-
centa uses these ATP-independent uptake transporters to import hy-
drophilic or charged molecules into the cell, some of which are then
used as hormonal substrates. As previously mentioned, they mainly
orchestrate uptake of molecules into the cell using coupled, passive,
and exchanger transport (Figure 1B). Substrates of this family are
extensive but include many nutritional compounds such as amino
acids, glucose and sugars, vitamins, fatty acids, inorganic and or-
ganic ions, oligopeptides, sulfated steroids, and thyroid hormones
[45]. Common drugs, such as NSAIDS, antibiotics, diuretics, and
anti-cancer drugs are transported by SLC transporters [60]. Mem-
bers of the family can be specific or polyspecific to these substrates
and are also involved in drug resistance. Since they transport a wide
range of toxins, common drugs, and nutritional compounds, these
transporters are extremely important in placental function. Exoge-
nous compounds have also been shown to overcome the maternal–
fetal barrier by acting as transport substrates of SLC membrane
transporter proteins (i.e., xenobiotics [61]), suggesting that placen-
tal expression of those transporters can control the exposure of the
fetus to potentially harmful compounds.
Ontogeny of placental SLC transporters
Currently, data are limited with respect to the gestational expres-
sion of this family. The human-specific transporter SLC22A11
is found at high levels in kidney and at the basolateral mem-
brane of the syncytiotrophoblast [57], where it imports sulfated
dehydroepiandrosterone (DHEAS) into the placenta and away from
the fetus [58] along with SLCO2B1, which has 10-fold lower affinity
for DHEAS. This uptake is necessary for the placental synthesis of
estrogens [62].
SLC22A4 and SLC22A5 are both expressed apically, although
their gestational expression profiles are currently unknown. Both
transporters import lactate and folate from the mother to the pla-
centa, while SLC22A5 also uptakes L-arginine from the maternal
side into the placenta and has been shown to import common drugs
e.g., antibiotics and antidepressants [53]. SLC22A3 plays an impor-
tant role in the transport of cationic compounds, but its full function
within the placenta remains unknown although it may be placenta-
specific as other tissues have very low expression [63]. SLC22A3 ex-
pression in pregnancy decreases between the first and third trimester
[64].
Understanding the ontogeny of SLCO transporters is of intense
interest due to their role in drug and essential hormone transport.
Patel et al. [24] have reported that there are marked changes in SLCO
transporter gene expression between the first and third trimester
human placenta. Their data showed an 8-fold decrease in SLCO1A2
and a 17-fold decrease in SLCO3A1 (with no change in SLCO1B1
or SLCO4A1) during this period although the study was limited by
a very small sample size (eight placentas at 9–12 weeks and six at
term). Others have reported, in contrast, that SLCO1A2 increases
toward term along with three other thyroid hormone transporters
(SLC16A2, SLC16A10, SLC7A5) [65]. This latter study had a much
larger sample size (n = 110) but the conflicting results highlight
the need for further developmental studies on the placenta to be
carried out. Prostaglandin (PG) transport is also mediated by SLCO
proteins. SLCO2A1 is involved in the clearance of PG and was found
to decrease with gestation [66].
Limitations in placental transport studies
Imperfect models for transport studies
Interspecies placental heterogeneity is considerable and conse-
quently, a nonprimate (specifically non great ape) animal model that
fully encompasses human placentation does not exist. This poses the
question whether transporter expression and activity measured in an
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Table 2. Comparing animal placentas used for comparative studies
against the human placenta.
Model Days to term Placental structure Interhemal layers
Human 266–280 Discoid 3
Mouse/rat 20–22 Discoid 5
Guinea pig 59–72 Discoid 3
Sheep 147 Cotyledonary 6
Comparison of gestational timing indicates that offspring are born at dif-
ferent stages of development. Placenta structure is classified according to gross
shape and points of maternal contact. Interhemal layers is the number of mem-
branes that separate the maternal and fetal circulations thus representing num-
ber of membranes that molecules must either diffuse or be transported across.
This highlights difficulties of using animal models to understand transport pro-
cesses in human placenta. All from maternal to fetal direction. Human: syncy-
tiotrophoblast; cytotrophoblast; fetal capillary endothelium. Mouse/rat: syn-
cytiotrophoblast; additional syncytial layer; sinusoidal giant cell layer. Guinea
pig: syncytiotrophoblast; basal lamina; fetal endothelium. Sheep: fetal mater-
nal endothelium; maternal stroma; uterine epithelium; trophoblast layer; fetal
stroma; endothelium of fetal capillary.
animal model has any relevance with respect to the human. Table 2
compares common animal models used for placental studies. There
are obvious advantages to using animal models (in particular, it is
just not possible to carry out many studies in the human for practical
or ethical reasons), but there are also many drawbacks. For exam-
ple, the syncytiotrophoblast in humans is not mimicked precisely by
other animals, other than great apes, and therefore studies on trans-
porter localization, or indeed time-dependent changes in expression,
cannot be confidently extrapolated using nonhuman placental tis-
sue. In addition, all animal models (and particularly rodents) have
a shorter gestation than the human. In many cases, this means that
they are not born at comparable stages of development so the dy-
namics of placental development is likely to be very different. Other
differences are described in more detail below.
Along with primates and rodents, the human placenta has a
discoid shape and hemochorial nature (maternal blood is in di-
rect contact with syncytiotrophoblast). However, significant differ-
ences can be seen in the gross structural morphology between species
(Table 2). There are marked differences between human and mouse
placenta as previously reviewed [67] but only the dissimilarities af-
fecting transporter studies will be discussed here. Rodents have an
additional inverted yolk sac placenta that exists alongside the nor-
mal placenta throughout the pregnancy and is essential for proper
development of the embryo [68]. It is impossible to separate this
secondary structure which can lead to questionable findings in feto-
maternal transfer studies. For some of the transport proteins, there
are no orthologs between human and rodent and transporters can
also be differentially localized, move dissimilar substrates, can be
regulated differently, and are differentially responsive to inhibitors
[69]. The syncytiotrophoblast in mice follows the same pattern
as humans but encompasses an additional syncytial layer and si-
nusoidal giant cell layer. In the architectural sense, they have a
labyrinthine exchange barrier whilst human have a villous barrier.
Trophoblast invasion also differs between the species; rats and mice
have a single cotyledon and three trophoblast cell layers whilst
humans have a cluster of cotyledons and a single syncytial layer
[70]. Functionally, human syncytiotrophoblast cells support both
endocrine and transporting function but in the mouse these roles
are geographically separated into a junctional and labyrinth zone,
respectively. One similarity between the mouse and the human is
the thinning of the syncytial membranes which increases diffusion
capacity toward term, making the late gestation rodent placenta
comparable to the human in nutrient diffusion conductance studies
(e.g., oxygen) [71].
The guinea pig is also commonly used as a model of placental
function and, in particular, for nutrient transport studies in order
to understand intrauterine growth restriction [72]. Anatomically,
guinea pigs have the complication of a subplacenta [73] (a convo-
luted area of trophoblasts which is separated from main placenta by
a junctional zone) and yolk sac that persists until term. However,
guinea pigs have a lengthier gestation than rats and mice and give
birth to precocial young and so the placenta must support further
developmental processes compared to other rodents and their altri-
cial young [74]. The guinea pig feto-maternal exchange interface is
also similar to human with a single layer (hemomonochorial) syn-
cytiotrophoblast (Table 2), although the cytotrophoblast does not
persist into the second half of gestation.
The sheep has a similar cotyledon to the human with comparable
fetal vasculature [75] and maturity at birth although it is structurally
different. The syncytiotrophoblast differs with more maternal layers
being retained, which increases the number of layers between mater-
nal and fetal vasculature (Table 2). There is also no maternal blood
lacunae so villi do not bathe directly in maternal blood. The syncy-
tiotrophoblast of the sheep is only perfused maternally as fetal cells
do not invade the syncytium, although they are interdigitated to aid
diffusion. The sheep placenta is not as well studied as, for example,
the guinea pig, since amino acid transporters have not been mapped
onto the syncytial layers as yet [76].
These species-dependent differences in syncytiotrophoblast de-
velopment, structure, and function create considerable problems
when relating animal studies to an understanding of transfer and
transporter activity in the human placenta. There are also other
problems to consider when extrapolating to the human. For ex-
ample, human endocrinology of pregnancy is unique due to the
high levels of estrogen generated by placental aromatization of fe-
tal adrenal dehydroepiandrosterone. Other species lack significant
placental aromatase (CYP19A1) [67], and this lack of CYP19A1
will also change the metabolic profile of the placenta affecting tox-
icity/toxicological studies. There are also molecular features which
are unique to human, affecting trophoblast invasion (Siglec-6 and
IMUP-2) [67].
Overall, the shortcomings of animal models described here
demonstrate the need for researchers to use human-derived tissue
in studies relating to placentation, common pregnancy disorders,
and toxicology. In order to minimize potentially misleading extrap-
olations from animal models, there have been human models estab-
lished at both ex vivo and in vitro levels. The term placental perfusion
model, although only a representation of the final pregnancy stage,
can be used, for example, to study transfer of solutes betweenmother
and fetus [77]. This has been useful, especially, in drug transport
studies [78] as it accurately represents the syncytiotrophoblast in a
physiological environment. Non-differentiated cell lines have also
been used to represent placental function at all weeks of gestation.
The BeWo cell line, established in 1968 by Pattillo and Gey [79],
is established for placental studies while the Jeg-3 and JAr cell lines
are also popular. These three immortalized cell lines are all derived
from human choriocarcinoma cells but they differ with respect to
proliferation and differentiation. It is vital, therefore, to characterize
transporter expression in each cell line in order to make informed
decisions about which one to use when studying the placental barrier
[27].
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Fetal age
There are, of course, a number of problems facing placental studies
using human tissue. It is possible to collect tissues from normally
progressing elective terminations (with a wide range of upper fetal
age limits, from 12–20 weeks in different countries) and from term
placentas but both require relevant ethical approvals which can be
an arduous process. Even when tissues can be collected, what is gen-
erally missing are representative samples from the weeks between
the latest elective termination date (after ∼20 weeks in the UK)
and preterm births (∼38 weeks). Therefore, data from this period
come largely from miscarriages where there are potential confound-
ing factors with respect to fetal and/or placental normality. An un-
representative age sample is a problem in studying the ontogeny
of transporter expression as the transporter of interest may not
be expressed during the timeframe leading to potentially erroneous
conclusions.
Fetal sex
A review by Clifton and Murphy [80] has stated that disregarding
the sex of the fetus whilst studying the placenta is improper practice.
While some studies do follow this advice [81, 82], most studies
disregard the sex of the fetus and pool placental samples (e.g. [17–19,
23]). Trophoblast cells are derived from the embryo, however, and
so they are sex-specific and recent studies have shown a marked
difference in placental transcript levels between male and female
fetuses [83]. There is also considerable evidence from other studies
to suggest functional differences in the placentas from different sexes.
As discussed above, influences of the intrauterine environment shape
fetal programming and may lead to disease onset later in life [84].
Pertinently, it has been reported that the time to onset and severity
of the resulting disorder differ between sexes [85]. Discrepancies
in growth ratios between males and females were recognized 50
years ago [86], and altered fetal growth is known to be intimately
associated with trophic delivery via the placenta [72]. This raises the
question whether some of these sex differences could be explained
by preferential transporter expression.
Currently, there are no data that show transporter expression
being influenced by fetal sex in the human placenta. However, the
endocrine environment of the fetus is sexually dimorphic and pla-
cental transporters are known to be regulated by hormones. ABCG2
expression, for example, has been reported to be altered by proges-
terone and estradiol exposure in the BeWo cell line [87]. Similarly,
recent evidence has suggested that the adverse pregnancy outcomes
in polycystic ovary syndrome could be caused by hormonal influence
on amino acid transport across the placenta due to much higher cir-
culating levels of androgens [88]. As the endocrine environment is
established with respect to fetal sex from as early as 8 weeks of
gestation, there may be sex-specific differential expression levels of
transporters in both the fetus and placenta during pregnancy. A fur-
ther complication with respect to the sex of the fetus has arisen
from a study [89], which reported that housekeeping genes com-
monly used to normalize human placental qPCR studies differ in
expression levels depending on fetal sex. This could either serve to
accentuate or reduce sex-specific differences, thereby invalidating the
study and highlighting the need to choose normalization strategies
carefully.
Medication in pregnancy
There is growing concern about the use of medication during preg-
nancy with evidence emerging for increasing use and prevalence of
medication by pregnant women [90]. Medicating during pregnancy
is often necessary to ameliorate acute or chronic illnesses of the
mother or even to treat problems with the developing fetus, such
as fetal arrhythmia or antiretroviral treatment if the mother is HIV
positive. A major problem however is that, for good reasons, preg-
nant woman are normally excluded from drug trials, leading to a
paucity of knowledge on correct dosage and usage of medications
in expectant mothers [91]. There is a risk both of underdosing or
overdosing and exposing the fetus to potential harm as many drugs
are able to reach the fetal compartment [92]. There is also the po-
tential for pregnancy-specific drug interactions as drugs crossing the
syncytiotrophoblast could saturate transporters; indeed, certain an-
tibiotics have been shown to block transporters [93]. Exogenous
glucocorticoids are the preferred treatment for woman at risk of
adverse pregnancy outcomes such as preterm birth and recurrent
miscarriages. Glucocorticoids have been shown, however, to reduce
amino acid transporter expression in vitro [94], and this altered
transporter expression in the placenta could be the reason glucocor-
ticoid use in pregnancy is linked to intrauterine growth restriction
[95].
Understanding the developmental expression of the transporters
may provide insights into both maternal and fetal medicating, es-
pecially with respect to when it is or is not safe to do so. ABC
expression, for instance, changes throughout gestation and any de-
crease in protective drug efflux would aid in drug delivery to the fetal
compartment. Nitrofurantoin, for example, is widely used to treat
urinary tract infections and continued treatment is necessary, even
in pregnancy, since a change in the bacterial environment height-
ens risk of preterm delivery. Nitrofurantoin is eliminated by ABCG2
[96] so any decrease in ABCG2 expression may harm the fetus, and
knowing this time frame (currently a controversy in the literature)
could inform medical professionals when to take precaution when
prescribing. Analgesics are extensively used during pregnancy (e.g.,
to ease maternal discomfort) and are considered safe but recent data
challenge this. A shortened anogenital distance has been observed,
for example, in male fetuses exposed to paracetamol during weeks
8–14 of gestation [97]. The mechanism of this effect is not clear but
paracetamol can decrease ABCG2 expression [98] suggesting that
it may induce nonphysiological changes to transporter expression
with downstream effects on placental function and fetal health—
particularly as ABCG2 is one of the key players at the maternal–fetal
interface.
In conclusion, there is a need to perform placental transporter
studies using human tissue with consideration of fetal sex and with
the largest age spectrum achievable. This would uncover more sex
and/or time differences in transporter expression, data which the
field is either lacking or unable to agree upon. It also may be
of interest to study transporter expression in the fetal liver from
the same pregnancy as it is the next major gate keeper to pre-
vent fetal exposure, receiving 70% of the blood from the placenta.
A better understanding of transporter regulation, both physiolog-
ically and pathologically, could shed light on molecular disposi-
tion within the placental and fetal compartments. Future studies
following these criteria may demonstrate to what extent, and why,
transporter expression is up/downregulated over the trimesters. It
is also important to relate mRNA and protein levels to trans-
porter activity within the human placenta, an area of research
that is far from conclusive. Furthermore, convincing establishment
of membrane localization of all identified transporters is required
so that an accurate “map” of transport directions can be estab-
lished.
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